Abstract

Objective. A multi-discriminator-based cycle generative adversarial network (MD-CycleGAN) model is proposed to synthesize higher-quality pseudo-CT from MRI images. Approach. MRI and CT images obtained at the simulation stage with cervical cancer were selected to train the model. The generator adopted DenseNet as the main architecture. The local and global discriminators based on a convolutional neural network jointly discriminated the authenticity of the input image data. In the testing phase, the model was verified by a fourfold cross-validation method. In the prediction stage, the data were selected to evaluate the accuracy of the pseudo-CT in anatomy and dosimetry, and they were compared with the pseudo-CT synthesized by GAN with the generator based on the architectures of ResNet, sUNet, and FCN. Main results. There are significant differences (P < 0.05) in the fourfold cross-validation results on the peak signal-to-noise ratio and structural similarity index metrics between the pseudo-CT obtained based on MD-CycleGAN and the ground truth CT (CTgt). The pseudo-CT synthesized by MD-CycleGAN had closer anatomical information to the CTgt with a root mean square error of 47.83 ± 2.92 HU, a normalized mutual information value of 0.9014 ± 0.0212, and a mean absolute error value of 46.79 ± 2.76 HU. The differences in dose distribution between the pseudo-CT obtained by MD-CycleGAN and the CTgt were minimal. The mean absolute dose errors of Dosemax, Dosemin, and Dosemean based on the planning target volume were used to evaluate the dose uncertainty of the four pseudo-CT. The u-values of the Wilcoxon test were 55.407, 41.82, and 56.208, and the differences were statistically significant. The 2%/2 mm-based gamma pass rate (%) of the proposed method was 95.45 ± 1.91, and the comparison methods (ResNet_GAN, sUnet_GAN, and FCN_GAN) were 93.33 ± 1.20, 89.64 ± 1.63, and 87.31 ± 1.94, respectively. Significance. The pseudo-CT images obtained based on MD-CycleGAN have higher imaging quality and are closer to the CTgt in terms of anatomy and dosimetry than other GAN models.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.